New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy
A new study led byBalázs Szigetiand with involvement of researchersBrandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harrisfound evidence of suggestibility predicting an antidepressant response for patients receiving psilocybin therapy.
The study aimed to understand the link between pre-trial expectancy, suggestibility and response to treatment in a previously conducted clinical trial comparing escitalopram andCOMPASS Pathways' (NASDAQ:CMPS) synthetic psilocybin, COMP360, in the treatment of 55 patients with Major Depressive Disorder (MDD.)Read more HERE.
EU Allocates Funds To Study...
Login or create a forever free account to read this news
Sign up/Log in